Innovent and Pfizer Collaborate to Develop 12 Cancer Treatments
Chinese company Innovent Biologics has announced a global collaboration with pharmaceutical giant Pfizer valued at <strong>$10.5 billion</strong> to develop <strong>12 cancer treatment programs</strong>. Innovent will receive an upfront payment of <strong>$650 million</strong>, with the potential to earn up to <strong>$9.85 billion</strong> tied to development and regulatory milestones.